In a filing, Compass Therapeutics Inc revealed its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on May 27 ’25. In the deal valued at $2.11 per share,10,000 shares were bought. As a result of this transaction, Schuetz Thomas J. now holds 6,480,825 shares worth roughly $16.72 million.
Then, GORDON CARL L sold 3,571,428 shares, generating $5,678,571 in total proceeds. Upon selling the shares at $1.59, the Director now owns 0 shares.
Before that, ORBIMED ADVISORS LLC sold 3,571,428 shares. Compass Therapeutics Inc shares valued at $5,678,571 were divested by the Director at a price of $1.59 per share. As a result of the transaction, ORBIMED ADVISORS LLC now holds 0 shares, worth roughly $0.0.
Leerink Partners upgraded its Compass Therapeutics Inc [CMPX] rating to an Outperform from a a Market perform in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late February with a ‘”a Buy”‘ rating. Piper Sandler began covering CMPX with “an Overweight” recommendation on February 19, 2025. D. Boral Capital started covering the stock on December 23, 2024. It rated CMPX as “a Buy”.
Price Performance Review of CMPX
On Friday, Compass Therapeutics Inc [NASDAQ:CMPX] saw its stock jump 3.20% to $2.58. Over the last five days, the stock has gained 20.00%. Compass Therapeutics Inc shares have risen nearly 77.93% since the year began. Nevertheless, the stocks have risen 100.00% over the past one year. While a 52-week high of $4.08 was reached on 02/11/25, a 52-week low of $0.76 was recorded on 04/01/25. SMA at 50 days reached $1.94, while 200 days put it at $2.01.
Levels Of Support And Resistance For CMPX Stock
The 24-hour chart illustrates a support level at 2.42, which if violated will result in even more drops to 2.34. On the upside, there is a resistance level at 2.56. A further resistance level may holdings at 2.63. The Relative Strength Index (RSI) on the 14-day chart is 78.08, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.29, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 0.00%. Stochastics %K at 97.14% indicates the stock is a selling.
